Citigroup’s Ensysce Biosciences ENSC Stock Holding History

Citigroup’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-20	Closed	-$62K	–	5957
2022 Q2	$62K	Buy	+20	New	+$56K	﹤0.01%	4447

Other funds holding ENSC

HVCM

HG Vora Capital Management New York $197M AUM 17.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MGIA

Moneta Group Investment Advisors St Louis, Missouri $13.5B AUM 24.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Citigroup's ENSC Position: Q3 2022 in Review

Citigroup sold out of Ensysce Biosciences (ENSC) in Q3 2022, closing a stake of 20 shares — an estimated $62K sold.

Citigroup first reported a position in ENSC in Q2 2022 and held it in 1 quarter. The position peaked at $62K in Q2 2022. 16 funds tracked by Wall St. Rank hold ENSC as of Q3 2022.

Citigroup reported no remaining Ensysce Biosciences position as of Q3 2022 after selling out during the quarter.
Citigroup sold 20 Ensysce Biosciences shares in Q3 2022, an estimated $62K.
Citigroup first reported a position in Ensysce Biosciences in Q2 2022 and held it in 1 quarter.
Citigroup's Ensysce Biosciences position peaked at $62K in Q2 2022.
16 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.